advertisement
Abstract #14252 Published in IGR 8-3
Effect of dorzolamide, brinzolamide, or bunazosin hydrochloride as the third concomitant medication for glaucoma
Shiba T; Inoue K; Wakakura M; Inouye J; Tomita GJapanese Journal of Clinical Ophthalmology 2006; 60: 907-911
PURPOSE: To evaluate the additive effect of dorzolamide, brinzolamide, or bunazosin hydrochloride in patients treated with beta-blocker and latanoprost. METHOD: This retrospective study was made on 39 eyes of 39 patients of primary open-angle glaucoma or normal-tension glaucoma. They were receiving beta-blocker and latanoprost. Dorzolamide, brinzolamide, or bunazosin were received as the third medication. Intraocular pressure (IOP) was measured up to 6 months after addition. RESULTS: Dorzoamide and bunazosin induced no significant changes in IOP for 6 months. Brinzolamide induced decreased IOP 1 and 3 months after addition. Differences in IOP reduction after 2 to 6 months were the same among the 3 groups. Rate of IOP reduction 6 months after addition was greater in dorzolamide and brinzolamide groups than in bunazosin group. CONCLUSION: There is a possibility that dorzolamide and brinzolamide induces more IOP reduction than bunazosin when used as the third concomitant medication. LA: Japanese
Dr. T. Shiba, Inouye Eye Hospital, 4-3 Kanda-Surugadai, Tokyo 101-0062, Japan
Classification:
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
